Global veterinary Parnell is a mid-sized, global veterinary pharmaceutical player with a presence in 15 countries and a growing portfolio across companion, production, and performance animals, signaling expanded cross-border sales opportunities and the potential to leverage international distribution channels.

New product launches Recent and upcoming product introductions such as Sevoflurane Inhalation Anesthetic and RESPIRmycin indicate active expansion of the anesthesia and antimicrobial segments, presenting targeted upsell and bundle packaging opportunities for clinics, distributors, and livestock operations.

Digital integration Parnell has invested in unique digital technology solutions (mySYNCH, on-farm packaging, and integration with veterinary workflows) that can be leveraged to offer value-added services, data-driven insights, and streamlined procurement, creating cross-sell potential with digital platforms.

Regulatory & manufacturing strength FDA-accredited sterile manufacturing facility in Sydney and a strong R&D/regulatory track record position Parnell as a reliable supplier for high-quality sterile products and accelerated market access, enabling partnerships for contract manufacturing, white-label opportunities, or joint ventures.

Growth through partnerships With a robust pipeline in anesthesia, orthopedics, laminitis, and antibiotics, plus a market-leading portfolio and a professional development-driven culture, there is potential to establish distribution collaborations, co-marketing arrangements, or regional sales partnerships to scale quickly in existing and adjacent markets.